HDAC6 and cholangiocarcinoma: Indeed, in some human tumors, the overexpression of HDAC6 is associated with more advanced tumor stages and higher tumor invasiveness, so the survival rate is low in cholangiocarcinoma, ovarian cancer, and acute myeloid leukemia (AML) [48–50].